In an analysis that included nearly 1,300 patients with large-vessel ischaemic stroke, earlier treatment with endovascular thrombectomy (intra-arterial use of a micro-catheter or other device to remove a blood clot) plus medical therapy (use of a clot dissolving agent) compared with medical therapy alone was associated with less disability at three months, according to a study appearing in the 27 September issue of JAMA.
The treatment of mechanical thrombectomy represents a highly effective therapy in patients with acute ischaemic stroke. This was recently proven by four randomised controlled trials (MR CLEAN, SWIFT-PRIME, EXTEND-IA, ESCAPE), in patients with a proximal large vessel occlusion. The ARTESp study, recently published by Sascha Prothmann, Department of Diagnostic and Interventional Neuroradiology at Klinikum rechts der Isar, et al, in the Journal of NeuroInterventional Surgery (JNIS) mirrors and reinforces the findings of the above mentioned trials.
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders
NIH-funded study suggests efforts to prevent risk factors should extend to those older than 65
Researchers have shown in mice how immune cells in the brain target and remove unused connections between brain cells during normal development. This research, supported by the National Institutes of Health, sheds light on how brain activity influences brain development, and highlights the newly found importance of the immune system in how the brain is wired, as well as how the brain forms new connections throughout life in response to change.
NIH-funded study could lead to new treatments for amblyopia.
NIH scientists develop technique that provides new insight into stroke
NIH-funded study helps answer decades old question about emergency blood pressure management options
Small blood clots called emboli are mostly known for traveling through the vasculature before they lodge and obstruct vessels, impeding blood and oxygen supply to organs like the lung. To stop excessive bleeding or the flow of blood into an aneurysm, clinicians harness the same principle by forming artificial therapeutic emboli that can plug blood-carrying vessels. Using steerable catheters, they place tiny soft metal coils or liquid embolic agents ("glues") into the affected artery to block the passage of blood.
Although cerebral aneurysms affect a substantial portion of the adult population, the risk of treatment including open brain surgery often outweighs the risks associated with rupture. With increasing numbers of unruptured aneurysms detected using noninvasive imaging techniques, there is an urgent need for a reliable method to distinguish aneurysms vulnerable to impending rupture from those that are presently robust and can be safely monitored. An international research team led by the University of Pittsburgh Swanson School of Engineering recently received a grant from the National Institutes of Health (NIH) to improve risk assessment and treatment of this devastating disease.
A Louisville patient is the first to be enrolled in a national clinical trial to test a new treatment for patients who have suffered a ruptured brain aneurysm. The trial, based at the University of Louisville under principal investigator Robert F. James, M.D., associate professor in the Department of Neurosurgery at UofL, will include eight other medical centers in the United States.
Following the onset of a stroke, restoring blood flow to the brain as quickly as possible is critical for preventing disability and improving the chances of recovery. This crucial window for treatment is a narrow one - about 4 ½ hours - and the earlier the treatment, the better the outcome.
The University of Alabama at Birmingham has received a BRAIN Initiative grant of $7.3 million over five years from the National Institutes of Health to study new technology that could improve outcomes from deep brain stimulation, an increasingly important treatment for Parkinson´s disease and other movement disorders.
In a first of its kind study, Mount Sinai researchers are using optimal coherence tomography (OCT) angiography to look at the earliest stages of glaucoma and identify characteristic patterns of different forms of glaucoma based on their vascular patterns. The research could lead doctors to diagnose glaucoma cases earlier than ever before and potentially slow down the progression of vision loss.
Research from Mayo Clinic included in the November issue of JAMA Neurology identifies a new biomarker for brain and spinal cord inflammation, allowing for faster diagnosis and treatment of patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos